# Bacteriotherapy in the Treatment of COVID-19

> **NCT04368351** · — · UNKNOWN · sponsor: **University of Roma La Sapienza** · enrollment: 70 (actual)

## Conditions studied

- COVID
- Pneumonia
- Diarrhea

## Interventions

- **DIETARY_SUPPLEMENT:** SivoMixx (200 billion)
- **DRUG:** Azithromycin
- **DRUG:** hydroxychloroquine

## Key facts

- **NCT ID:** NCT04368351
- **Lead sponsor:** University of Roma La Sapienza
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-07-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04368351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04368351, "Bacteriotherapy in the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04368351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*